N-methyl-N-ethyl-2(3H)-benzimidazolone | 17445-64-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N-methyl-N-ethyl-2(3H)-benzimidazolone
• 英文别名: 1-ethyl-3-methyl-1H-benzo[d]imidazol-2(3H)-one；1-Methyl-3-ethyl-benzimidazolon；1-Ethyl-3-methyl-benzimidazol-2-on；1-ethyl-3-methyl-1,3-dihydro-benzoimidazol-2-one；NoName_3544；1-ethyl-3-methylbenzimidazol-2-one
• CAS: 17445-64-6
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: ZIYRJIZPYNCEGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-甲基苯并咪唑 、 alkaline earth salt of/the/ methylsulfuric acid 在 水 、 碘 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙酸乙酯 、 甲醇 为溶剂， 生成 N-methyl-N-ethyl-2(3H)-benzimidazolone
  参考文献：
  名称：

  唑类 的无金属C（sp 2）–H官能化：K 2 CO 3 / I 2介导的氧化，氨基化和氨基化†

  摘要：

  通过使用可商购的简单K 2 CO 3 / I 2试剂组合，可以实现多种唑类的直接C2-H氧化和亚胺化。碘化唑加成物，产生通过所述原位生成N-杂环碳烯的，为C2-H氧化，亚胺化，和唑类的胺化的关键中间体。重要的是，这些反应在温和的条件下以高至优异的产率进行，可扩展至大量并显示出广泛的底物范围。有趣的是，这种直接的C2-H胺化方法使我们能够获得各种具有药理活性的N 6-烷基或N 6芳基取代的苯并咪唑并喹唑啉酮骨架通过分子内CH串联进行一锅反应。

  DOI：

  10.1039/c8ob00535d

文献信息

• Ramoplanin derivatives possessing antibacterial activity
  申请人：Raju G. Bore

  公开号：US20060211603A1

  公开（公告）日：2006-09-21

  Novel ramoplanin derivatives are disclosed. These ramoplanin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against gram positive bacteria, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

  新型拉莫普兰衍生物已被披露。这些拉莫普兰衍生物表现出抗菌活性。由于本发明的化合物对革兰氏阳性细菌表现出强效活性，它们是有用的抗微生物药剂。该化合物的合成方法和使用方法也已被披露。
• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Li Jim

  公开号：US20100111900A1

  公开（公告）日：2010-05-06

  Compounds having the formula I wherein R 1 , R 2 , R 3a , R 3b , R 3c , R 4 , R 5 and p are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  具有以下化学式I的化合物，其中R1、R2、R3a、R3b、R3c、R4、R5和p的定义如本文所述，是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
• ORGANIC COMPOUND, CHARGE-TRANSPORTING MATERIAL, COMPOSITION FOR CHARGE-TRANSPORTING MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE
  申请人：IIDA Koichiro

  公开号：US20090284134A1

  公开（公告）日：2009-11-19

  An organic compound having excellent heat resistance, an excellent amorphous nature, an excellent ability to transport charges, highly excited singlet and triplet states, and excellent solubility in an organic solvent is an organic compound represented by Formula (I): wherein Ar 1 represents an optionally-substituted aromatic hydrocarbon group, an optionally-substituted aromatic heterocyclic group, or an optionally-substituted alkyl group; Ar 2 represents an optionally-substituted aromatic hydrocarbon group or an optionally-substituted aromatic heterocyclic group; R 1 and R 2 each represent a hydrogen atom or a substituent, and R 1 and R 2 may be bonded to each other to form a ring; and Q is represented by Formula (I-1) or (I-2): wherein Ar 3 to Ar 5 each represent an optionally-substituted aromatic hydrocarbon group or an optionally-substituted aromatic heterocyclic group, and Ar 3 and Ar 4 may be bonded to each other to form a ring.

  具有优异热稳定性、优异非晶性、优异电荷传输能力、高度激发单重态和三重态状态、以及在有机溶剂中优异溶解性的有机化合物，可以用公式（I）表示，其中Ar1代表可选取代的芳香烃基、可选取代的芳香杂环基或可选取代的烷基；Ar2代表可选取代的芳香烃基或可选取代的芳香杂环基；R1和R2分别代表氢原子或取代基，R1和R2可相互连接形成环；Q由公式（I-1）或（I-2）表示，其中Ar3至Ar5分别代表可选取代的芳香烃基或可选取代的芳香杂环基，Ar3和Ar4可相互连接形成环。
• PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF
  申请人：Shanghai Shaletech Technology Co., Ltd.

  公开号：EP3216786A1

  公开（公告）日：2017-09-13

  The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

  本发明公开了一类嘧啶或吡啶化合物、其药学上可接受的盐、立体异构体、原药和溶液、其制备方法和药物组合物及其药物用途。这些化合物可以抑制表皮生长因子受体蛋白酶的变体，从而有效抑制多种肿瘤细胞的生长。这些化合物可用于制备抗肿瘤药物，用于治疗、联合治疗或预防各种不同的癌症。这些化合物可以克服现有的第一代表皮生长因子受体抑制剂（如吉非替尼、厄洛替尼等）引起的耐药性。特别是，这些化合物可用于制备治疗或预防由表皮生长因子受体变体（如 L858R 激活突变体、Exon19 缺失激活突变体和 T790M 耐药突变体）介导的疾病、紊乱、失调或病症的药物。
• US7220735B2
  申请人：——

  公开号：US7220735B2

  公开（公告）日：2007-05-22